Cerus reports record preliminary Q4/FY2021 product revenue, guides 2022 up 20-25%

CERUS CORP

2022-FY EPS reported -$0.32 revenue$159,518,000

Q4 2021 preliminary product revenue $39.9M, up 41% YoY from $28.2M.
Full-year 2021 preliminary product revenue $130.9M, above guidance of $127-129M.
2022 product revenue guidance $157-164M, representing 20-25% growth vs. 2021.
More than half of U.S. platelets now treated with INTERCEPT on a run-rate basis.
Nationwide launch of INTERCEPT Fibrinogen Complex after first BLA approval for Gulf Coast blood center.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.